The CD3 antigen inhibitor Tzield (teplizumab-mzwv) has won FDA approval to delay stage 3 type 1 diabetes in individuals at least 8 years old. A vial of Tzield will have a wholesale cost of $13,850, announced the drug’s developer Provention Bio (Nasdaq:PRVB). The drug is administered as an intravenous infusion once daily for 14 consecutive days, resulting in…